Summary
The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, < 65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p.o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders’ rate was 65% in the AH group and 82% in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00± 0.51 to 3.25 ± 0.83 ml min−1 m−2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min−1 m−2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated anti-hypertensive treatment in both adult and elderly patients.
Similar content being viewed by others
References
Zachariah PK, Sheps SG, Schirger A (1986) Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Am J Cardiol 57: 74D-79D
Reinfrank J, Eckardt A, Hahn KJ (1987) Long term multicenter study of verapamil SR 240 mg in hypertension. In: Fleckenstein A, Laragh JH (eds) Hypertension — the next decade: verapamil in focus. Churchull-Livingstone, Edinburgh London, pp 307–313
Abernethy DR, Schwartz JB, Todd EL, Lichi R, Snow E (1986) Verpamil pharmacodynamics and disposition in young and elderly hypertensive patients. Ann Intern Med 105: 329–332
Buhler FR, Hulthen UL, Kiowsky W, Bolli P (1987) Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci 439–442
Cox PJ, O’Boyle CA, Mee F, Kelly J, Atkins N, Coakley D, O’Brein ET, O’Malley K (1988) The antihypertensive efficacy of verapamil in evaluation by ambulatory blood pressure measurement. J Hum Hpyertens 2: 41–47
Richards AM, Tonolo G, Leckie BJ, Robertson IS (1987) Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens 5: 227–236
Kirk RE (1968) Experimental design: procedures for the behavioural sciences. Brooks/Cole, Belmont, California
SPSS Inc. (1986) SPSS-x user’s guide. McGraw-Hill, New York
Lennart Hulthen U, Bolli P, Amann FW, Kiowski W, Buhler FR (1982) Verapamil-induced vasodilatation is enhanced in essential hypertension. J Cardiovasc Pharmacol 4: S313-S318
Schmieder RE, Messerli FN, Garavaglia GE, Nunez BD (1987) Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 75: 1030–1036
Lang RE, Tholken HG, Anten D, Luit FC, Unger TH (1985) Atrial natriuretic factor: a circulating hormone stimulated by volume loading. Nature 314: 264–266
Ledsome JR, Wilson N, Couneya CA, Rankin AJ (1985) Release of atrial natriuretic peptide by atrial distension. Can J Physiol Pharmacol 63: 739–742
Agnoletti G, Rodela A, Ferrari R, Harrys P (1987) Release of atrial natriuretic peptide-like immunoreactive material during stretching of the rat atrium in vitro. J Mol Cell Cardiol 19: 217–220
Burnett JC, Kao PC, Hu D, Heser DW, Reeder GS (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145–1147
Nakaoka H, Imataka K, Amano M, Fujii J, Yamaji T (1985) Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med 313: 892–893
Rascher W, Tulassay T, Lang RE (1985) Atrial natriuretic peptide in plasma of volume overloaded children with chronic renal failure. Lancet I: 303–305
Yamaji T, Ishibashi M, Nakaoka H, Amano M, Fujii J (1985) Possible role for atrial natriuretic peptide in polyuria associated with paroxysmal atrial arrhythmias. Lancet I: 1211
Schiaffrin EI, Gutkowska J, Kuchel O, Cantin M, Genest J (1985) Plasma concentration of atrial natriuretic factor in patients with paroxysmal atrial tachycardia. N Engl J Med 312: 1196–1197
Saccomanno G, Antonicelli R, Campanari G, Paciaroni E (1989) Effects of mode and rate of pacing on atrial natriuretic peptide release in patients with permanent pacemakers. Curr Ther Res 46(4): 762–767
Sagnella GA, Markandu ND, Shore AC, MacGregor GA (1986) Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet I: 179–181
Kohono M, Yasunai K, Matsuura T, Takeda T (1987) Circulating atrial natriuretic polypeptide in essential hypertension. Am Heart J 113: 1160–1163
Larochelle P, Cusson J, Gutkowska EL, Schiffrin P, Genest J, Cantin M (1987) Plasma atrial natriuretic factor concentrations in essential and renovascular hypertension. Br Med J 249: 1249–1252
Nilsson P, Schersten B, Melander A, Lindholm L, Horn R, Hesch RD (1988) Atrial natriuretic peptide and blood pressure in a geographically defined population. Lancet II: 883–886
Sugawara A, Nakao K, Sakamoto M (1985) Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet II: 1426–1427
Antonicelli R, Melappioni M, Campanari G, Foschi F, Paciaroni E (1989) Evaluation of plasmatic ANP levels in subjects affected by essential arterial hypertension and in a group of patients undergoing dialysis. Int J Cardiol 25 [Suppl 1]: 21–29
Knorr M, Locher R, Strimpel M, Edmonds D, Vetter W (1986) Effects of ANP on angiotensin II-induced increase of cytosolic free calcium in cultured smooth muscle cells. J Hypertens 4 [Suppl 2]: S67-S69
Winquist RJ (1985) The relaxant effects of ANF on vascular smooth muscle. Life Sci 37: 1081–1087
Van Bortel LMAB, Schiffers PMH, Boehm ROB, Mooy JMV, Rahn KH (1989) The influence of a chronic treatment with verapamil on plasma human ANP levels in young and elderly hypertensive patients (abstract). Proceedings of the 4th European Meeting on Hypertension, Milan, June 18–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Antonicelli, R., Tomassini, P.F., Galletti, P. et al. Age-related antihypertensive and haemodynamic effects of verapamil SR: Clinical results and effects on atrial natriuretic peptide. Eur J Clin Pharmacol 39 (Suppl 1), S29–S33 (1990). https://doi.org/10.1007/BF03216272
Issue Date:
DOI: https://doi.org/10.1007/BF03216272